Brivanib

Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β[1].

Product Specifications

CAS Number

[649735-46-6]

Product Name Alternative

BMS-540215

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; VEGFR

Type

Reference compound

Related Pathways

Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Brivanib.html

Concentration

10mM

Purity

99.92

Solubility

DMSO : ≥ 50 mg/mL

Smiles

FC1=C(OC2=NC=NN3C2=C(C(OC[C@H](O)C)=C3)C)C=CC4=C1C=C(C)N4

Molecular Formula

C19H19FN4O3

Molecular Weight

370.38

Precautions

H302, H315, H319, H335

References & Citations

[1]Bhide RS, et al. Discovery and preclinical studies of (R) -1- (4- (4-fluoro-2-methyl-1H-indol-5-yloxy) -5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy) propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem, 2006, 49 (7), 2143-2146.|[2]Huynh H, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res, 2008, |[3]Nakamura I, et al. Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. PLoS One. 2015 Nov 3;10 (11) :e0142355.